Featured Post

ALERT! PLEASE TAKE ACTION!

The July 12, 2019 issue of The Flinn Report revealed that The Department of Healthcare and Family Services has proposed an amendment (“propo...

September 30, 2019

House Members Warn Against Relaxing Restriction on Abortion Drug Mifepristone

Fifty-three members of the House of Representatives sent a letter to the FDA to argue against Planned Parenthood's request that restrictions be removed from the distribution of the chemical abortion drug mifepristone. The drug has been linked to thousands of complications and 24 deaths in the United States alone, and a generic version of mifepristone, which up to this point had only been sold under the name Mifeprex, has been approved by the FDA.

An excerpt from the representatives' letter states, “We vigorously opposed calls by Planned Parenthood and other pro-abortion advocates to remove the REMS [Risk Evaluation and Mitigation Strategy] for mifepristone. Allowing the drug to be available without medical supervision will have dire consequences for women and children.” Click here for more.